BOLT
Bolt Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.31
+6.68%Year over year
Reported trailing growth
- Revenue
- +12.8%
- EBITDA
- +44.8%
- EBIT
- +45.2%
- EPS
- —
- Free cash flow
- +38.6%
- Operating cash flow
- +38.8%
Forward estimates
Based on analyst estimates
- Revenue
- -92.5%
- EBITDA
- +43.8%
- EPS
- +40.0%
Three-year CAGR
- Revenue
- +10.3%
- EBITDA
- +51.7%
- EBIT
- +52.6%
- Net income
- +47.1%
- EPS
- —
- Free cash flow
- +34.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026